Register for full access to Citywire’s Fund Manager database, news and analysis. Registration is free and only takes a minute.

AXA Framlington Health R Inc

Ranked 6 out of 8 in - Pharmaceuticals & Health Care over 12 months
All calculations are in GBP

Managed by

Mark Hargraves

Mark Hargraves applies a blended stock selection style with a bias towards GARP for the AXA Framlington European unit trust. He joined AXA Framlington in 2000 after spells with United Friendly Asset Management and SG Hambros Fund Managers. Hargraves launched his career with a two-year stint as an assistant product manager at Abbey National from 1994 to 1996. He holds a Masters degree in Finance from the London Business School and a BSc Hons in Geography from Bristol University. He is also an Associate of the Institute of Investment Management and Research. When he is not managing money Hargraves enjoys the pursuits of golf, tennis and mountaineering.

Objective

To achieve capital growth through investment in healthcare and medical services and product companies worldwide. Investment will be in producers of pharmaceuticals, biotechnology firms, medical device and instrument manufacturers, distributors of healthcare products, care providers and managers, and other healthcare services companies.

Performance

Pharmaceuticals & Health Care over : 30/11/2013 - 30/11/2014

Total Return

Quarterly Performance

to 30/09/2014 Annual Q1 Q2 Q3 Q4
2014 3.5% 3.6% 8.6%
2013 34.6% 20.9% 0.9% 3.3% 6.8%
2012 11.2% 7.0% 3.5% 3.8% -3.2%
2011 5.3% 3.4% 5.2% -8.9% 6.3%
2010 16.2% 15.1% -9.3% 1.9% 9.3%
2009 15.2% -4.3% 1.6% 13.1% 4.7%
2008 -7.7% -13.7% 3.6% 4.7% -1.4%
2007 8.0% 2.7% 2.0% 2.9% 0.1%
2006 -11.9% 4.5% -15.4% 0.1% -0.3%
2005 15.2% -6.3% 11.8% 8.9% 1.0%
2004 3.4% 5.0% 1.4% -6.7% 4.0%
2003 32.9% 0.3% 19.8% 7.1% 3.3%
2002 -43.5% -10.2% -25.6% -16.2% 0.9%
2001 -14.7% -28.6% 28.5% -26.2% 26.1%
2000 116.6% 49.8% 30.5% 28.9% -14.1%
1999 44.7% -8.2% 5.7% 3.2% 44.3%
1998 -7.3% 9.2% -7.2% -19.9% 14.1%
1997 9.8% 4.1% 2.2% 14.8% -10.1%
1996 7.4% 15.6% 3.8% -3.2% -7.5%
1995 24.5%

Month by Month Performance

Returns Vs Risk

Asset Allocation

Breakdown

31/08/2014

Top 10 Holdings

Stock Size
ROCHE HOLDING G PAR 5.95
Gilead Sciences Inc ORD 5.50
Novartis AG ORD 5.10
UnitedHealth Group Inc ORD 2.98
Celgene Corp ORD 2.51
Shire PLC ORD 2.45
AstraZeneca PLC ORD 2.42
Express Scripts Holding Co ORD 2.37
McKesson Corp ORD 2.33
Allergan Inc ORD 2.13
31/08/2014

Registered For Sale In

  1. Singapore
  2. United Kingdom

Fund Info

  • Launch date24/04/1987
  • Share Class size433Mn
  • Base currencyGBP
  • ISIN GB0005753719

Purchase Info

  • Min. initial investment1,000
  • Min. additional investment50

Charges

  • Annual management1.5%
  • Initial investment5.5

Related News

Gemma Game to exit AXA Investment Managers

Game was head of healthcare at the firm and had managed the AXA Framlington Health fund since July 2011.

AAA-rated Bowie: corporate bonds could fall up to 40%

Chris Bowie, head of credit at Ignis Asset Management, believes corporate bonds have limited upside and could see a capital loss of up to 40% if real gilt yields adjust.

GLG: why the tech sector is set to face a big battle

GLG’s managers Anthony Burton and Philip Pearson believe the technology sector is set to face ‘significant disruption’ due to Amazon’s loss-leading approach with its new Kindle Fire tablet.

Axa Framlington appoints Linden Thomson to healthcare team

Axa Investment Managers has hired Linden Thomson as a portfolio manager in the Axa Framlington healthcare team.

Deane Donnigan resigns from AXA Framlington

Deane Donnigan, lead manager of the AXA Framlington Health Fund, has resigned after 13 years at the firm.  

Powell to launch healthcare fund at Polar Capital

Citywire A-rated Gareth Powell will run a new long-only healthcare fund for Polar Capital when he joins the firm from Axa Framlington.

Biotech manager Gareth Powell leaves AXA Framlington

(Update: Powell joining Polar Capital) AXA Framlington Biotechnology fund manager Gareth Powell has left the firm for Polar Capital.

Sector Watch: Specialist managers build on property boom

Property funds aided returns in the Specialist sector, with Standard Life Investments’ Andrew Jackson leading the pack.

Fund Result: signs of life in healthcare

Dr Deane Donnigan, manager of the £410 million Framlington Health fund, believes healthcare stocks look very attractively valued across most areas.

Sectorwatch: Breathing new life into Healthcare

Healthcare and biotech funds may languish at the foot of the specialist sector rankings for the 12-month period to the end of June, but the performance of these funds in the second quarter of 2005 suggests a pulse still beats in a number of these portfolios.

...more...

Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in GBP).